Latest news with #ophthalmic
Reuters
30-05-2025
- Business
- Reuters
Essilorluxottica to buy Optegra eyecare clinics
MILAN, May 30 (Reuters) - Essilorluxottica ( opens new tab has entered an agreement to buy Optegra ophthalmic clinics from MidEuropa, as the Franco-Italian eyewear group aims to expand in the medical technology industry, the companies said on Friday. Financial details of the transaction, which is expected to close later this year, were not disclosed. The Optegra group operates a network of over 70 eye hospitals and diagnostic facilities in the UK, Czech Republic, Poland, Slovakia and the Netherlands under the Optegra, Lexum and Iris brands. It serves both publicly reimbursed and private-pay patients, providing treatments and vision correction procedures such as cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement and laser eye surgery. "With the acquisition of Optegra, we are stepping into a new frontier – one where comprehensive eyecare, advanced diagnostics, therapeutic interventions and surgical treatments come together in one seamless platform", Essilorluxottica CEO Francesco Milleri and deputy CEO Paul du Saillant said in a statement. Essilorluxottica was advised by Rothschild for the transaction. It is aiming to expand beyond its traditional lenses and sunglasses products, into complementary sectors characterised by a strong technological component, such as Ray-Ban Meta smart glasses or hearing aids applied to glasses.
Yahoo
26-05-2025
- Business
- Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - Market Expands Amid Surge in Diabetic Retinopathy Cases
Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like Lumenis Be Ltd. and IRIDEX are innovating to meet growing demands. Recent FDA approvals highlight ongoing advancements in portable laser technologies. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "U.S. Ophthalmic Photocoagulator Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Country: (U.S.)" report has been added to U.S. ophthalmic photocoagulator market is poised for substantial growth, with projections indicating a rise from US$ 52.62 million in 2025 to US$ 74.3 million by 2032. This expansion reflects a compound annual growth rate (CAGR) of 5.05% over the forecast period from 2025 to 2032. With a growing elderly population and rising prevalence of eye-related conditions such as diabetic retinopathy and macular degeneration, the demand for advanced ophthalmic laser treatments is accelerating across the photocoagulators are precision laser systems designed to treat retinal diseases by coagulating blood vessels in the retina. These devices play a critical role in treating vision-threatening conditions such as diabetic retinopathy, age-related macular degeneration, and macular edema. As technological advancements continue to reshape the ophthalmology Analysis, there is a clear shift toward minimally invasive and highly precise treatment the adoption of multicolor scan laser photocoagulators is on the rise due to their ability to deliver multiple wavelengths, enabling targeted treatment across various retinal layers. These systems offer improved patient outcomes and reduced side effects, making them a preferred choice for eye care professionals and patients DriversA key factor fueling market expansion is the increasing prevalence of diabetes and associated retinal complications. Diabetic retinopathy remains a leading cause of vision impairment among adults in the United States. With the diabetic population continuing to rise, there is a parallel increase in the demand for effective retinal treatments, such as laser advancements in multicolor and wavelength laser technologies are transforming treatment possibilities. New-generation lasers offer ophthalmologists improved precision, flexibility, and the ability to tailor treatments based on individual patient conditions. These capabilities are particularly beneficial in outpatient settings, contributing to the growing popularity of these systems in ambulatory surgical centers and ophthalmic OpportunityThe emergence of portable and compact laser systems presents a lucrative opportunity for market players. As the healthcare system shifts toward outpatient care and point-of-service treatment, portable photocoagulators offer greater flexibility and access, particularly in smaller clinics and rural settings. These devices are easier to operate, more cost-effective, and suitable for a wider range of treatment significant opportunity lies in the increasing number of outpatient laser procedures. These treatments provide advantages such as faster recovery, reduced costs, and enhanced patient convenience. The transition from hospital-based to outpatient treatment modalities is expected to expand the customer base for photocoagulator manufacturers, especially those that offer scalable, user-friendly ChallengesDespite favorable growth conditions, the market is not without challenges. One of the primary restraints is limited reimbursement for photocoagulation procedures. Stringent insurance policies and high out-of-pocket costs may deter patients from pursuing necessary treatment or adhering to follow-up schedules. Furthermore, for healthcare providers, limited reimbursement often affects the adoption of advanced laser systems, especially in budget-constrained challenge stems from competition with alternative treatments. Anti-VEGF injections and newer pharmacological therapies are increasingly preferred for conditions like age-related macular degeneration and diabetic macular edema. These alternatives offer non-laser treatment options that are less invasive and often more comfortable for patients, posing a potential threat to the uptake of traditional laser-based AnalysisThe U.S. ophthalmic photocoagulator market benefits significantly from a well-established healthcare infrastructure and a high level of awareness regarding eye health. Increasing investments in ophthalmology research, expanding healthcare access through outpatient services, and a growing aging population make the U.S. a strong growth engine for the widespread adoption of advanced diagnostic and therapeutic solutions, the country is experiencing a shift toward personalized and preventive eye care. This evolution is driving the demand for devices that offer precise, customizable treatments - a trend well-supported by the introduction of multicolor scan lasers and minimally invasive Landscape Companies are focused on expanding their product portfolios, enhancing treatment precision, and increasing accessibility to advanced photocoagulation devices across healthcare settings. Key Players Lumenis Be Ltd. IRIDEX Corporation Alcon Inc. Quantel Medical (Lumibird Medical) NIDEK CO., LTD. Johnson & Johnson Vision Care, Inc. TOPCON CORPORATION Bausch & Lomb Incorporated Meridian Medical Group Lab Medica Systems Pvt. Ltd Norlase OD-OS Zeiss A.R.C. Laser GmbH MEDA Co., Ltd. Market SegmentationBy Wavelength: Yellow Scan Laser Photocoagulator Red Scan Laser Photocoagulator Green Scan Laser Photocoagulator Multicolor Scan Laser Photocoagulator By Application: Macular Edema Age-related Macular Degeneration Diabetic Retinopathy Glaucoma Others By End User: Hospitals Ophthalmic Clinics Ambulatory Surgical Centers Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Fast Company
12-05-2025
- Business
- Fast Company
Eye drop recall: Nearly 76,000 cases of eye care products are feared to be of ‘unacceptable quality'
If you're a frequent eye drop user, now's the time to check your medicine cabinet: The pharmaceutical lab BRS Analytical Service, LLC has issued a voluntary recall of five different ophthalmic solutions, including some eye drops and artificial tears, due to concerns that the products may be of 'unacceptable quality.' Here's what to know: What is the reason for the recall? According to a notice published by the distributor AvKare, the recall was initiated when a U.S. Food and Drug Administration (FDA) audit found 'manufacturing cGMP deviations' in the production of the five eye products. CGMP, or Current Good Manufacturing Practice, refers to the required manufacturing process guidelines set by the FDA for a certain item. Per the AvKare notice, 'Health Hazard to the user is unknown, cGMP deviations may lead to products of unacceptable quality, and it is not possible to rule out patient risks resulting from use of these products.' Separately, an FDA enforcement report surrounding the five products notes that there was a 'lack of assurance of sterility' found during the agency's audit. BRS Analytical Service voluntarily initiated the five recalls on April 23. On May 6, the FDA classified each as a Class II, meaning it is considered a situation in which exposure to the product may cause 'reversible adverse health consequences,' or where the probability of serious health consequences is 'remote.' Which products are being recalled? The recall encompasses five products, totaling over 75,000 cases of ophthalmic solution, shipped over a two-year period: May 26, 2023, to April 21, 2025. The products include: NDC# 50268-043-15 Artificial Tears Ophthalmic Solution; recall number D-0404-2025 NDC# 50268-066-15 Carboxymethylcellulose Sodium Ophthalmic Gel 1%; recall number D-0405-2025 NDC# 50268-068-15 Carboxymethylcellulose Sodium Ophthalmic Solution; recall number D-0406-2025 NDC# 50268-126-15 Lubricant Eye Drops Solution; recall number D-0407-2025 NDC# 50268-678-15 Polyvinyl Alcohol Ophthalmic Solution; recall number D-0408-2025 Detailed lots numbers and specific expiration dates can be found here. Where were the products sold? According to the FDA, the items were distributed nationwide in the U.S., though specific states and stores were not listed. What should I do if I have one of the recalled products? If you have a recalled eye solution, do not use it. Instead, AvKare requests that you follow the instructions listed in its notice to alert the company that you received the recalled product, and then ship the affected items back to its headquarters.
Yahoo
06-05-2025
- Business
- Yahoo
Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain
MEXICO CITY, May 6, 2025 /CNW/ - Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery, upon regulatory approval. Apotex Inc. Logo (CNW Group/Apotex Inc.) APP13007 was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the corticosteroid clobetasol propionate, and it is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. This novel formulation proved statistically and clinically superior to its matching placebo in Phase 3 trials in the United States (p<0.001). This license agreement for the Mexican market adds to Apotex's existing exclusive rights to this product in Canada. "At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy," said Alok Kanti, President, Apotex International. "Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include the Mexico territory," said Erick Co, President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as soon as possible." About Apotex Inc. Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at
